Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’

作者: K-L G Spindler , N Pallisgaard , R F Andersen , A Jakobsen

DOI: 10.1038/BJC.2014.115

关键词: CamptothecinPlasma dnaColorectal cancerCancer researchProto-Oncogene ProteinsBiologyBioinformaticsIrinotecanKRAS

摘要: Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’

参考文章(9)
John Ploen, Karen-Lise G Spindler, Rikke F Andersen, Anders Jakobsen, Niels Pallisgaard, Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. Anticancer Research. ,vol. 34, pp. 845- 850 ,(2014)
K G Spindler, A L Appelt, N Pallisgaard, R F Andersen, A Jakobsen, KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer British Journal of Cancer. ,vol. 109, pp. 3067- 3072 ,(2013) , 10.1038/BJC.2013.633
KL Spindler, MM Sorensen, N Pallisgaard, RF Andersen, Havelund, BM, J Ploen, U Lassen, AK Jakobsen, Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma Acta Oncologica. ,vol. 52, pp. 963- 970 ,(2013) , 10.3109/0284186X.2013.776175
Karen-Lise Garm Spindler, Niels Pallisgaard, Rikke Fredslund Andersen, John Ploen, Anders Jakobsen, Pemetrexed and Gemcitabine for Chemotherapy Refractory Colorectal Cancer—Results of a Phase II and Translational Research Study Journal of Cancer Therapy. ,vol. 4, pp. 44- 50 ,(2013) , 10.4236/JCT.2013.46A2006
Sandra Misale, Rona Yaeger, Sebastijan Hobor, Elisa Scala, Manickam Janakiraman, David Liska, Emanuele Valtorta, Roberta Schiavo, Michela Buscarino, Giulia Siravegna, Katia Bencardino, Andrea Cercek, Chin-Tung Chen, Silvio Veronese, Carlo Zanon, Andrea Sartore-Bianchi, Marcello Gambacorta, Margherita Gallicchio, Efsevia Vakiani, Valentina Boscaro, Enzo Medico, Martin Weiser, Salvatore Siena, Federica Di Nicolantonio, David Solit, Alberto Bardelli, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature. ,vol. 486, pp. 532- 536 ,(2012) , 10.1038/NATURE11156
Luis A. Diaz Jr, Richard T. Williams, Jian Wu, Isaac Kinde, J. Randolph Hecht, Jordan Berlin, Benjamin Allen, Ivana Bozic, Johannes G. Reiter, Martin A. Nowak, Kenneth W. Kinzler, Kelly S. Oliner, Bert Vogelstein, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature. ,vol. 486, pp. 537- 540 ,(2012) , 10.1038/NATURE11219
Torben Frøstrup Hansen, Rikke Fredslund Andersen, Niels Pallisgaard, Karen-Lise Garm Spindler, John Pløen, Nina Keldsen, Jan Lindebjerg, Flemming Brandt Sørensen, Anders Jakobsen, None, A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer Colorectal cancer. ,vol. 3, pp. 135- 145 ,(2014) , 10.2217/CRC.13.85
D. Tougeron, T. Lecomte, J.C. Pagès, C. Villalva, C. Collin, A. Ferru, J.M. Tourani, C. Silvain, P. Levillain, L. Karayan-Tapon, Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer Annals of Oncology. ,vol. 24, pp. 1267- 1273 ,(2013) , 10.1093/ANNONC/MDS620
Karen-Lise Garm Spindler, Niels Pallisgaard, Ivan Vogelius, Anders Jakobsen, Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan Clinical Cancer Research. ,vol. 18, pp. 1177- 1185 ,(2012) , 10.1158/1078-0432.CCR-11-0564